These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26757259)
1. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Conceição M; Mendonça L; Nóbrega C; Gomes C; Costa P; Hirai H; Moreira JN; Lima MC; Manjunath N; Pereira de Almeida L Biomaterials; 2016 Mar; 82():124-37. PubMed ID: 26757259 [TBL] [Abstract][Full Text] [Related]
2. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3. Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052 [TBL] [Abstract][Full Text] [Related]
3. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684 [TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease. Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979 [TBL] [Abstract][Full Text] [Related]
5. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100 [TBL] [Abstract][Full Text] [Related]
6. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049 [TBL] [Abstract][Full Text] [Related]
7. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Gonçalves N; Simões AT; Cunha RA; de Almeida LP Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556 [TBL] [Abstract][Full Text] [Related]
11. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362 [TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease/spinocerebellar ataxia type 3. Rufino-Ramos D; Albuquerque PR; Leandro K; Carmona V; Martins IM; Fernandes R; Henriques C; Lobo D; Faro R; Perfeito R; Mendonça LS; Pereira D; Gomes CM; Nobre RJ; Pereira de Almeida L Mol Ther; 2023 May; 31(5):1275-1292. PubMed ID: 37025062 [TBL] [Abstract][Full Text] [Related]
13. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3. Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111 [TBL] [Abstract][Full Text] [Related]
14. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574 [TBL] [Abstract][Full Text] [Related]
15. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007 [TBL] [Abstract][Full Text] [Related]
16. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease. Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575 [TBL] [Abstract][Full Text] [Related]
17. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. Alves S; Nascimento-Ferreira I; Auregan G; Hassig R; Dufour N; Brouillet E; Pedroso de Lima MC; Hantraye P; Pereira de Almeida L; Déglon N PLoS One; 2008 Oct; 3(10):e3341. PubMed ID: 18841197 [TBL] [Abstract][Full Text] [Related]
18. Safety profile of the intravenous administration of brain-targeted stable nucleic acid lipid particles. Conceição M; Mendonça L; Nóbrega C; Gomes C; Costa P; Hirai H; Moreira JN; Lima MC; Manjunath N; de Almeida LP Data Brief; 2016 Mar; 6():700-5. PubMed ID: 26958628 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185 [TBL] [Abstract][Full Text] [Related]
20. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]